Hydra Capital
Hydra Capital is a diversified incubation platform working at the cutting edge of ageing research to improve the human condition through developing new therapies to delay biological ageing, extend longevity, and in the immediate term, treat poorly addressed diseases. Hydra invests in teams working on independent, parallel molecular processes known to underlie ageing, and encourages collaboration to achieve the best clinical outcomes. Currently, Hydra has mature drug candidates that extend lifespan but will be used in the immediate term to treat female infertility, obesity, pulmonary fibrosis, and liver disease. If successful, any one of these therapies could drastically improve our quality of life, and extend human lifespan.